Narayana Hrudayalaya Ltd. (NH) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

CompoundingAI Research Updated July 27, 2026 3 min read

Narayana Hrudayalaya is navigating a transition phase as it integrates its UK-based Practice Plus Group acquisition while managing a complex regulatory environment for medical supplies in India. Investors will be focused on whether the consolidated EBITDA margin can stabilise following the dilution from international operations and the extent of the drag from the loss-making insurance segment.

Quick Details

Results date	July 31, 2026
Quarter	Q1 FY 2026-2027
Previous quarter revenue	Rs. 25,938 Mn
Previous quarter PAT	Rs. 2,240 Mn
Market cap	Rs. 41961.8 Cr
CMP	Rs. 2054.0

Narayana Hrudayalaya Ltd. Q1 Results Date and Time

The company has scheduled its board meeting for July 31, 2026, to consider the financial results for the quarter ended June 30, 2026.

What to expect from Narayana Hrudayalaya Ltd.'s Q1 FY27 results

Consolidated revenue is expected to show significant year-over-year growth as the UK acquisition, consolidated from November 6, 2025, contributes for the first full first-quarter of a new financial year. While the India standalone business historically maintains a margin trajectory of 21–24%, consolidated EBITDA margins will likely remain capped in the mid-to-high-teens due to the structurally lower margins of the UK operations, which reported a 20.8% consolidated margin in Q4 FY26. Procurement costs for oncology drugs are expected to face mild pressure following the June 12, 2026, NPPA ceiling-price increases for cisplatin to Rs. 10.89/ml and carboplatin to Rs. 90.74/ml. The insurance segment remains a profitability drag, having widened its full-year loss to Rs. 1,242 Mn in FY26, and management's commentary on the break-even timeline for this unit will be a critical focal point. Finance costs, which rose 124.4% year-over-year in Q4 FY26 to Rs. 912.9 Mn, will remain under scrutiny given the company's leverage position and the impact of the rupee's recent depreciation.

Key Things To Watch

Operational and Margin Trajectory: Monitoring the impact of the UK integration and seasonal India demand trends.

Consolidated EBITDA margin stability versus the 20.8% reported in Q4 FY26 to assess if UK dilution is bottoming
Occupancy rate and ARPOB trends to gauge the underlying health of the India standalone business post-fiscal year-end
Impact of NPPA drug price revisions on the cost of medical supplies as a percentage of revenue

Strategic and Financial Updates: Tracking capital allocation and the performance of loss-making segments.

Insurance segment PBIT loss trajectory to determine if the rate of widening is slowing
Net Debt/EBITDA progression against the management target of less than 2.5x
Updates on the Rs. 3,000 Cr India capex plan for FY26-FY28 and progress on new bed additions

Frequently Asked Questions

How did the UK acquisition impact Narayana Hrudayalaya's financials in the previous quarter?

The consolidation of the UK-based Practice Plus Group contributed to a 75.8% year-over-year revenue growth in Q4 FY26. However, it also led to a 530 bps year-over-year compression in consolidated EBITDA margins as the UK contracts operate at structurally lower margins.

What is the status of the company's debt and finance costs?

As of March 31, 2026, total borrowings stood at Rs. 48,661 Mn with a Debt/Equity ratio of 1.29x. Finance costs increased 124.4% year-over-year in Q4 FY26, partly driven by the GBP 150 Mn debt associated with the UK acquisition.

Is the insurance segment profitable for the company?

No, the insurance segment is currently a drag on consolidated profitability, having reported a PBIT loss of Rs. 599.7 Mn in Q4 FY26 alone. The full-year loss for this segment widened to Rs. 1,242 Mn in FY26, which is five times the loss recorded in FY25.